Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted
Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Confo Therapeutics today announced that it has entered into a collaborative
Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company's clinical development program including